#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. Discussion
1-1	0-2	3.	_	_	_	_
1-2	3-13	Discussion	abstract	new	_	_

#Text=This study showed that the cotreatment of G. lucidum extracts ( GLE ) and quercetin ( QCT ) exerted synergistic antitumor and antiviral activities against SNU719 EBVaGC cells .
2-1	14-18	This	abstract[2]	new[2]	coref	20-12[152_2]
2-2	19-24	study	abstract[2]	new[2]	_	_
2-3	25-31	showed	_	_	_	_
2-4	32-36	that	_	_	_	_
2-5	37-40	the	abstract[3]	new[3]	coref	3-4[16_3]
2-6	41-52	cotreatment	abstract[3]	new[3]	_	_
2-7	53-55	of	abstract[3]	new[3]	_	_
2-8	56-58	G.	abstract[3]|person|substance[6]	new[3]|new|new[6]	_	_
2-9	59-66	lucidum	abstract[3]|event|substance[6]	new[3]|new|new[6]	_	_
2-10	67-75	extracts	abstract[3]|substance[6]	new[3]|new[6]	_	_
2-11	76-77	(	_	_	_	_
2-12	78-81	GLE	abstract	new	coref	4-4[29_0]
2-13	82-83	)	_	_	_	_
2-14	84-87	and	_	_	_	_
2-15	88-97	quercetin	substance	new	_	_
2-16	98-99	(	_	_	_	_
2-17	100-103	QCT	abstract	new	coref	4-9
2-18	104-105	)	_	_	_	_
2-19	106-113	exerted	_	_	_	_
2-20	114-125	synergistic	abstract[11]	new[11]	coref	16-3[125_11]
2-21	126-135	antitumor	abstract|abstract[11]	new|new[11]	coref	12-3
2-22	136-139	and	abstract[11]	new[11]	_	_
2-23	140-149	antiviral	abstract[11]	new[11]	_	_
2-24	150-160	activities	abstract[11]	new[11]	_	_
2-25	161-168	against	_	_	_	_
2-26	169-175	SNU719	substance|animal[14]	new|new[14]	coref|coref	3-15|3-15[20_14]
2-27	176-182	EBVaGC	abstract|animal[14]	new|new[14]	coref	14-1
2-28	183-188	cells	animal[14]	new[14]	_	_
2-29	189-190	.	_	_	_	_

#Text=Low concentrations of the cotreatment resulted in both the synergistic activation of cytotoxicity in SNU719 cells and the suppression of tumor development in MKN1-EBV xenograft mice .
3-1	191-194	Low	substance[15]	new[15]	coref	7-1[50_15]
3-2	195-209	concentrations	substance[15]	new[15]	_	_
3-3	210-212	of	substance[15]	new[15]	_	_
3-4	213-216	the	substance[15]|abstract[16]	new[15]|giv[16]	coref	7-5[53_16]
3-5	217-228	cotreatment	substance[15]|abstract[16]	new[15]|giv[16]	_	_
3-6	229-237	resulted	abstract	new	coref|none	20-3[148_0]|3-6[0_171]
3-7	238-240	in	_	_	_	_
3-8	241-245	both	event[17]	new[17]	_	_
3-9	246-249	the	event[17]	new[17]	_	_
3-10	250-261	synergistic	event[17]	new[17]	_	_
3-11	262-272	activation	event[17]	new[17]	_	_
3-12	273-275	of	event[17]	new[17]	_	_
3-13	276-288	cytotoxicity	event[17]|abstract[18]	new[17]|new[18]	coref	4-11[31_18]
3-14	289-291	in	event[17]|abstract[18]	new[17]|new[18]	_	_
3-15	292-298	SNU719	event[17]|abstract[18]|substance|animal[20]	new[17]|new[18]|giv|giv[20]	coref|coref	3-6|4-17[35_20]
3-16	299-304	cells	event[17]|abstract[18]|animal[20]	new[17]|new[18]|giv[20]	_	_
3-17	305-308	and	_	_	_	_
3-18	309-312	the	event[21]	new[21]	_	_
3-19	313-324	suppression	event[21]	new[21]	_	_
3-20	325-327	of	event[21]	new[21]	_	_
3-21	328-333	tumor	event[21]|object|event[23]	new[21]|new|new[23]	_	_
3-22	334-345	development	event[21]|event[23]	new[21]|new[23]	_	_
3-23	346-348	in	event[21]	new[21]	_	_
3-24	349-357	MKN1-EBV	event[21]|abstract|animal[25]|animal[26]	new[21]|new|new[25]|new[26]	_	_
3-25	358-367	xenograft	event[21]|animal[25]|animal[26]	new[21]|new[25]|new[26]	_	_
3-26	368-372	mice	event[21]|animal[26]	new[21]|new[26]	_	_
3-27	373-374	.	_	_	_	_

#Text=The addition of a low concentration GLE to QCT reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .
4-1	375-378	The	event[27]	new[27]	coref	5-3[36_27]
4-2	379-387	addition	event[27]	new[27]	_	_
4-3	388-390	of	event[27]	new[27]	_	_
4-4	391-392	a	event[27]|abstract[29]	new[27]|giv[29]	coref	6-14[0_29]
4-5	393-396	low	event[27]|abstract[28]|abstract[29]	new[27]|new[28]|giv[29]	_	_
4-6	397-410	concentration	event[27]|abstract[28]|abstract[29]	new[27]|new[28]|giv[29]	_	_
4-7	411-414	GLE	event[27]|abstract[29]	new[27]|giv[29]	_	_
4-8	415-417	to	event[27]	new[27]	_	_
4-9	418-421	QCT	event[27]|abstract	new[27]|giv	coref	6-21[48_0]
4-10	422-432	reinforced	_	_	_	_
4-11	433-445	QCT-mediated	abstract[31]	giv[31]	coref	7-11[54_31]
4-12	446-458	cytotoxicity	abstract[31]	giv[31]	_	_
4-13	459-462	and	_	_	_	_
4-14	463-475	QCT-mediated	abstract|abstract[33]	new|new[33]	coref|coref	7-14[55_33]|24-9
4-15	476-485	apoptosis	abstract[33]	new[33]	_	_
4-16	486-488	in	abstract[33]	new[33]	_	_
4-17	489-495	SNU719	abstract[33]|substance|animal[35]	new[33]|giv|giv[35]	coref|coref	7-17|7-17[57_35]
4-18	496-501	cells	abstract[33]|animal[35]	new[33]|giv[35]	_	_
4-19	502-503	.	_	_	_	_

#Text=Furthermore , the addition also activated the EBV lytic gene promoter and upregulated EBV genes .
5-1	504-515	Furthermore	_	_	_	_
5-2	516-517	,	_	_	_	_
5-3	518-521	the	event[36]	giv[36]	_	_
5-4	522-530	addition	event[36]	giv[36]	_	_
5-5	531-535	also	_	_	_	_
5-6	536-545	activated	_	_	_	_
5-7	546-549	the	person[40]	new[40]	coref	8-6[62_40]
5-8	550-553	EBV	abstract|person[40]	new|new[40]	coref	5-14
5-9	554-559	lytic	place|person[40]	new|new[40]	coref	8-8
5-10	560-564	gene	abstract|person[40]	new|new[40]	coref	8-9
5-11	565-573	promoter	person[40]	new[40]	_	_
5-12	574-577	and	_	_	_	_
5-13	578-589	upregulated	_	_	_	_
5-14	590-593	EBV	abstract|abstract[42]	giv|new[42]	coref|coref	8-7|8-13[64_42]
5-15	594-599	genes	abstract[42]	new[42]	_	_
5-16	600-601	.	_	_	_	_

#Text=Interestingly , ganoderic acid A ( GAA ) , an effective molecule of GLE also showed similar bioactive features with QCT like GLE .
6-1	602-615	Interestingly	_	_	_	_
6-2	616-617	,	_	_	_	_
6-3	618-627	ganoderic	substance[43]	new[43]	_	_
6-4	628-632	acid	substance[43]	new[43]	_	_
6-5	633-634	A	substance[43]	new[43]	_	_
6-6	635-636	(	_	_	_	_
6-7	637-640	GAA	abstract	new	coref	7-5[51_0]
6-8	641-642	)	_	_	_	_
6-9	643-644	,	_	_	_	_
6-10	645-647	an	substance[45]	new[45]	_	_
6-11	648-657	effective	substance[45]	new[45]	_	_
6-12	658-666	molecule	substance[45]	new[45]	_	_
6-13	667-669	of	substance[45]	new[45]	_	_
6-14	670-673	GLE	substance[45]|abstract	new[45]|giv	coref	6-23
6-15	674-678	also	_	_	_	_
6-16	679-685	showed	_	_	_	_
6-17	686-693	similar	abstract[47]	new[47]	_	_
6-18	694-703	bioactive	abstract[47]	new[47]	_	_
6-19	704-712	features	abstract[47]	new[47]	_	_
6-20	713-717	with	abstract[47]	new[47]	_	_
6-21	718-721	QCT	abstract[47]|abstract[48]	new[47]|giv[48]	coref	7-8[0_48]
6-22	722-726	like	abstract[47]|abstract[48]	new[47]|giv[48]	_	_
6-23	727-730	GLE	abstract[47]|abstract[48]|abstract	new[47]|giv[48]|giv	coref	8-17
6-24	731-732	.	_	_	_	_

#Text=The low concentrations of the GAA and QCT cotreatment reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .
7-1	733-736	The	substance[50]	giv[50]	_	_
7-2	737-740	low	substance[50]	giv[50]	_	_
7-3	741-755	concentrations	substance[50]	giv[50]	_	_
7-4	756-758	of	substance[50]	giv[50]	_	_
7-5	759-762	the	substance[50]|abstract[51]|abstract[53]	giv[50]|giv[51]|giv[53]	coref	8-3[58_53]
7-6	763-766	GAA	substance[50]|abstract[51]|abstract[53]	giv[50]|giv[51]|giv[53]	_	_
7-7	767-770	and	substance[50]|abstract[53]	giv[50]|giv[53]	_	_
7-8	771-774	QCT	substance[50]|abstract|abstract[53]	giv[50]|giv|giv[53]	coref	9-1
7-9	775-786	cotreatment	substance[50]|abstract[53]	giv[50]|giv[53]	_	_
7-10	787-797	reinforced	_	_	_	_
7-11	798-810	QCT-mediated	abstract[54]	giv[54]	_	_
7-12	811-823	cytotoxicity	abstract[54]	giv[54]	_	_
7-13	824-827	and	_	_	_	_
7-14	828-840	QCT-mediated	abstract[55]	giv[55]	coref	10-7[0_55]
7-15	841-850	apoptosis	abstract[55]	giv[55]	_	_
7-16	851-853	in	abstract[55]	giv[55]	_	_
7-17	854-860	SNU719	abstract[55]|substance|animal[57]	giv[55]|giv|giv[57]	coref	10-25[80_57]
7-18	861-866	cells	abstract[55]|animal[57]	giv[55]|giv[57]	_	_
7-19	867-868	.	_	_	_	_

#Text=Furthermore , the cotreatment activated the EBV lytic gene promoter and upregulated EBV genes , like GLE .
8-1	869-880	Furthermore	_	_	_	_
8-2	881-882	,	_	_	_	_
8-3	883-886	the	abstract[58]	giv[58]	_	_
8-4	887-898	cotreatment	abstract[58]	giv[58]	_	_
8-5	899-908	activated	_	_	_	_
8-6	909-912	the	person[62]	giv[62]	_	_
8-7	913-916	EBV	abstract|person[62]	giv|giv[62]	coref	8-13
8-8	917-922	lytic	place|person[62]	giv|giv[62]	_	_
8-9	923-927	gene	abstract|person[62]	giv|giv[62]	coref	22-12
8-10	928-936	promoter	person[62]	giv[62]	_	_
8-11	937-940	and	_	_	_	_
8-12	941-952	upregulated	_	_	_	_
8-13	953-956	EBV	abstract|abstract[64]	giv|giv[64]	coref	13-8
8-14	957-962	genes	abstract[64]	giv[64]	_	_
8-15	963-964	,	abstract[64]	giv[64]	_	_
8-16	965-969	like	abstract[64]	giv[64]	_	_
8-17	970-973	GLE	abstract[64]|abstract	giv[64]|giv	coref	18-1[129_0]
8-18	974-975	.	_	_	_	_

#Text=QCT has been shown to exhibit potential anticancer properties owing to its antiproliferative , growth factor suppressive and antioxidant effects .
9-1	976-979	QCT	abstract	giv	ana	9-12
9-2	980-983	has	_	_	_	_
9-3	984-988	been	_	_	_	_
9-4	989-994	shown	_	_	_	_
9-5	995-997	to	_	_	_	_
9-6	998-1005	exhibit	_	_	_	_
9-7	1006-1015	potential	abstract[68]	new[68]	_	_
9-8	1016-1026	anticancer	abstract|abstract[68]	new|new[68]	_	_
9-9	1027-1037	properties	abstract[68]	new[68]	_	_
9-10	1038-1043	owing	_	_	_	_
9-11	1044-1046	to	_	_	_	_
9-12	1047-1050	its	abstract|abstract[73]	giv|new[73]	coref|coref	10-4|12-2[94_73]
9-13	1051-1068	antiproliferative	abstract[73]	new[73]	_	_
9-14	1069-1070	,	abstract[73]	new[73]	_	_
9-15	1071-1077	growth	abstract|abstract[71]|abstract[72]|abstract[73]	new|new[71]|new[72]|new[73]	coref	10-16[77_0]
9-16	1078-1084	factor	abstract[71]|abstract[72]|abstract[73]	new[71]|new[72]|new[73]	_	_
9-17	1085-1096	suppressive	abstract[72]|abstract[73]	new[72]|new[73]	_	_
9-18	1097-1100	and	abstract[73]	new[73]	_	_
9-19	1101-1112	antioxidant	abstract[73]	new[73]	_	_
9-20	1113-1120	effects	abstract[73]	new[73]	_	_
9-21	1121-1122	.	_	_	_	_

#Text=In addition , QCT can induce apoptosis , where it has been shown to reduce the growth of tumors and inhibit the spread of malignant cells .
10-1	1123-1125	In	_	_	_	_
10-2	1126-1134	addition	_	_	_	_
10-3	1135-1136	,	_	_	_	_
10-4	1137-1140	QCT	abstract	giv	coref	12-6
10-5	1141-1144	can	_	_	_	_
10-6	1145-1151	induce	_	_	_	_
10-7	1152-1161	apoptosis	abstract	giv	ana	10-10
10-8	1162-1163	,	_	_	_	_
10-9	1164-1169	where	_	_	_	_
10-10	1170-1172	it	abstract	giv	coref	15-1
10-11	1173-1176	has	_	_	_	_
10-12	1177-1181	been	_	_	_	_
10-13	1182-1187	shown	_	_	_	_
10-14	1188-1190	to	_	_	_	_
10-15	1191-1197	reduce	_	_	_	_
10-16	1198-1201	the	abstract[77]	giv[77]	ana	11-3[0_77]
10-17	1202-1208	growth	abstract[77]	giv[77]	_	_
10-18	1209-1211	of	abstract[77]	giv[77]	_	_
10-19	1212-1218	tumors	abstract[77]|object	giv[77]|new	_	_
10-20	1219-1222	and	_	_	_	_
10-21	1223-1230	inhibit	_	_	_	_
10-22	1231-1234	the	event[79]	new[79]	_	_
10-23	1235-1241	spread	event[79]	new[79]	_	_
10-24	1242-1244	of	event[79]	new[79]	_	_
10-25	1245-1254	malignant	event[79]|animal[80]	new[79]|giv[80]	coref	11-25[91_80]
10-26	1255-1260	cells	event[79]|animal[80]	new[79]|giv[80]	_	_
10-27	1261-1262	.	_	_	_	_

#Text=Moreover , it inhibited chemical carcinogen-induced cell transformation , which was evident as cell viability decreased , ROS generation and microRNA-21 elevation occurred in cancer cells .
11-1	1263-1271	Moreover	_	_	_	_
11-2	1272-1273	,	_	_	_	_
11-3	1274-1276	it	abstract	giv	_	_
11-4	1277-1286	inhibited	_	_	_	_
11-5	1287-1295	chemical	event[83]	new[83]	_	_
11-6	1296-1314	carcinogen-induced	event[83]	new[83]	_	_
11-7	1315-1319	cell	place|event[83]	new|new[83]	coref	11-14
11-8	1320-1334	transformation	event[83]	new[83]	_	_
11-9	1335-1336	,	event[83]	new[83]	_	_
11-10	1337-1342	which	event[83]	new[83]	_	_
11-11	1343-1346	was	event[83]	new[83]	_	_
11-12	1347-1354	evident	event[83]	new[83]	_	_
11-13	1355-1357	as	event[83]	new[83]	_	_
11-14	1358-1362	cell	event[83]|place|abstract[85]	new[83]|giv|new[85]	coref	15-31
11-15	1363-1372	viability	event[83]|abstract[85]	new[83]|new[85]	_	_
11-16	1373-1382	decreased	event[83]	new[83]	_	_
11-17	1383-1384	,	event[83]	new[83]	_	_
11-18	1385-1388	ROS	event[83]|substance|abstract[87]	new[83]|new|new[87]	_	_
11-19	1389-1399	generation	event[83]|abstract[87]	new[83]|new[87]	_	_
11-20	1400-1403	and	event[83]	new[83]	_	_
11-21	1404-1415	microRNA-21	event[83]|abstract|substance[89]	new[83]|new|new[89]	ana	12-2[0_89]
11-22	1416-1425	elevation	event[83]|substance[89]	new[83]|new[89]	_	_
11-23	1426-1434	occurred	event[83]	new[83]	_	_
11-24	1435-1437	in	_	_	_	_
11-25	1438-1444	cancer	abstract|animal[91]	new|giv[91]	coref|coref	15-11[114_91]|18-18[135_0]
11-26	1445-1450	cells	animal[91]	giv[91]	_	_
11-27	1451-1452	.	_	_	_	_

#Text=Besides its antitumor effects , QCT has been shown to have antiviral activity through its anti-infective and anti-replicative abilities .
12-1	1453-1460	Besides	_	_	_	_
12-2	1461-1464	its	substance|abstract[94]	giv|giv[94]	ana|coref	12-15|21-1[158_94]
12-3	1465-1474	antitumor	abstract|abstract[94]	giv|giv[94]	coref	15-15
12-4	1475-1482	effects	abstract[94]	giv[94]	_	_
12-5	1483-1484	,	_	_	_	_
12-6	1485-1488	QCT	abstract	giv	coref	13-16
12-7	1489-1492	has	_	_	_	_
12-8	1493-1497	been	_	_	_	_
12-9	1498-1503	shown	_	_	_	_
12-10	1504-1506	to	_	_	_	_
12-11	1507-1511	have	_	_	_	_
12-12	1512-1521	antiviral	abstract[96]	new[96]	_	_
12-13	1522-1530	activity	abstract[96]	new[96]	_	_
12-14	1531-1538	through	_	_	_	_
12-15	1539-1542	its	substance|abstract[98]	giv|new[98]	_	_
12-16	1543-1557	anti-infective	abstract[98]	new[98]	_	_
12-17	1558-1561	and	abstract[98]	new[98]	_	_
12-18	1562-1578	anti-replicative	abstract[98]	new[98]	_	_
12-19	1579-1588	abilities	abstract[98]	new[98]	_	_
12-20	1589-1590	.	_	_	_	_

#Text=The replication of herpes viruses , including EBV , was found to be affected by QCT .
13-1	1591-1594	The	abstract[99]	new[99]	_	_
13-2	1595-1606	replication	abstract[99]	new[99]	_	_
13-3	1607-1609	of	abstract[99]	new[99]	_	_
13-4	1610-1616	herpes	abstract[99]|animal|animal[101]	new[99]|new|new[101]	_	_
13-5	1617-1624	viruses	abstract[99]|animal[101]	new[99]|new[101]	_	_
13-6	1625-1626	,	abstract[99]|animal[101]	new[99]|new[101]	_	_
13-7	1627-1636	including	abstract[99]|animal[101]	new[99]|new[101]	_	_
13-8	1637-1640	EBV	abstract[99]|animal[101]|abstract	new[99]|new[101]|giv	coref	14-10
13-9	1641-1642	,	_	_	_	_
13-10	1643-1646	was	_	_	_	_
13-11	1647-1652	found	_	_	_	_
13-12	1653-1655	to	_	_	_	_
13-13	1656-1658	be	_	_	_	_
13-14	1659-1667	affected	_	_	_	_
13-15	1668-1670	by	_	_	_	_
13-16	1671-1674	QCT	abstract	giv	coref	16-1
13-17	1675-1676	.	_	_	_	_

#Text=EBVaGC exhibits mixed characteristics of both gastric carcinoma and EBV .
14-1	1677-1683	EBVaGC	abstract	giv	coref	15-11
14-2	1684-1692	exhibits	_	_	_	_
14-3	1693-1698	mixed	abstract[105]	new[105]	_	_
14-4	1699-1714	characteristics	abstract[105]	new[105]	_	_
14-5	1715-1717	of	abstract[105]	new[105]	_	_
14-6	1718-1722	both	abstract[105]|object[106]	new[105]|new[106]	coref	32-11[233_106]
14-7	1723-1730	gastric	abstract[105]|object[106]	new[105]|new[106]	_	_
14-8	1731-1740	carcinoma	abstract[105]|object[106]	new[105]|new[106]	_	_
14-9	1741-1744	and	abstract[105]	new[105]	_	_
14-10	1745-1748	EBV	abstract[105]|abstract	new[105]|giv	coref	15-3
14-11	1749-1750	.	_	_	_	_

#Text=Apoptosis and EBV lytic reactivation can control the fate of EBVaGC cells , where antitumor agents can induce apoptosis and antiviral agents can stimulate EBV lytic reactivation to further aggravate cell lysis .
15-1	1751-1760	Apoptosis	abstract|abstract[109]	giv|new[109]	coref|coref	15-19|20-18[155_109]
15-2	1761-1764	and	abstract[109]	new[109]	_	_
15-3	1765-1768	EBV	abstract[109]|abstract|event[111]	new[109]|giv|new[111]	coref|coref	15-25|15-25[120_111]
15-4	1769-1774	lytic	abstract[109]|event[111]	new[109]|new[111]	_	_
15-5	1775-1787	reactivation	abstract[109]|event[111]	new[109]|new[111]	_	_
15-6	1788-1791	can	_	_	_	_
15-7	1792-1799	control	_	_	_	_
15-8	1800-1803	the	abstract[112]	new[112]	_	_
15-9	1804-1808	fate	abstract[112]	new[112]	_	_
15-10	1809-1811	of	abstract[112]	new[112]	_	_
15-11	1812-1818	EBVaGC	abstract[112]|abstract|animal[114]	new[112]|giv|giv[114]	coref|coref	16-9|18-18[136_114]
15-12	1819-1824	cells	abstract[112]|animal[114]	new[112]|giv[114]	_	_
15-13	1825-1826	,	_	_	_	_
15-14	1827-1832	where	_	_	_	_
15-15	1833-1842	antitumor	abstract|person[116]	giv|new[116]	coref|coref	15-21[118_116]|16-3[124_0]
15-16	1843-1849	agents	person[116]	new[116]	_	_
15-17	1850-1853	can	_	_	_	_
15-18	1854-1860	induce	_	_	_	_
15-19	1861-1870	apoptosis	abstract	giv	coref	20-18[154_0]
15-20	1871-1874	and	_	_	_	_
15-21	1875-1884	antiviral	person[118]	giv[118]	coref	28-13[204_118]
15-22	1885-1891	agents	person[118]	giv[118]	_	_
15-23	1892-1895	can	_	_	_	_
15-24	1896-1905	stimulate	_	_	_	_
15-25	1906-1909	EBV	abstract|event[120]	giv|giv[120]	coref|coref	20-22[157_120]|22-11
15-26	1910-1915	lytic	event[120]	giv[120]	_	_
15-27	1916-1928	reactivation	event[120]	giv[120]	_	_
15-28	1929-1931	to	_	_	_	_
15-29	1932-1939	further	_	_	_	_
15-30	1940-1949	aggravate	_	_	_	_
15-31	1950-1954	cell	place|abstract[122]	giv|new[122]	coref	25-24[188_0]
15-32	1955-1960	lysis	abstract[122]	new[122]	_	_
15-33	1961-1962	.	_	_	_	_

#Text=QCT exhibits both antitumor and antiviral activities against EBVaGC .
16-1	1963-1966	QCT	abstract	giv	coref	17-5
16-2	1967-1975	exhibits	_	_	_	_
16-3	1976-1980	both	abstract[124]|abstract[125]	giv[124]|giv[125]	coref|coref	30-4[0_124]|30-4[212_125]
16-4	1981-1990	antitumor	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
16-5	1991-1994	and	abstract[125]	giv[125]	_	_
16-6	1995-2004	antiviral	abstract[125]	giv[125]	_	_
16-7	2005-2015	activities	abstract[125]	giv[125]	_	_
16-8	2016-2023	against	abstract[125]	giv[125]	_	_
16-9	2024-2030	EBVaGC	abstract[125]|abstract	giv[125]|giv	coref	32-20
16-10	2031-2032	.	_	_	_	_

#Text=This dual function of QCT is likely to be synergistic .
17-1	2033-2037	This	abstract[127]	new[127]	coref	36-13[257_127]
17-2	2038-2042	dual	abstract[127]	new[127]	_	_
17-3	2043-2051	function	abstract[127]	new[127]	_	_
17-4	2052-2054	of	abstract[127]	new[127]	_	_
17-5	2055-2058	QCT	abstract[127]|abstract	new[127]|giv	coref	21-11
17-6	2059-2061	is	_	_	_	_
17-7	2062-2068	likely	_	_	_	_
17-8	2069-2071	to	_	_	_	_
17-9	2072-2074	be	_	_	_	_
17-10	2075-2086	synergistic	_	_	_	_
17-11	2087-2088	.	_	_	_	_

#Text=GLE , containing polysaccharides and triterpenes , is known to suppress the proliferation and metastatic potential of breast cancer cells by inhibiting Akt , AP-1 and NF-κB .
18-1	2089-2092	GLE	abstract[129]	giv[129]	coref	19-3[0_129]
18-2	2093-2094	,	abstract[129]	giv[129]	_	_
18-3	2095-2105	containing	abstract[129]	giv[129]	_	_
18-4	2106-2121	polysaccharides	abstract[129]|substance	giv[129]|new	_	_
18-5	2122-2125	and	abstract[129]	giv[129]	_	_
18-6	2126-2137	triterpenes	abstract[129]|abstract	giv[129]|new	_	_
18-7	2138-2139	,	_	_	_	_
18-8	2140-2142	is	_	_	_	_
18-9	2143-2148	known	_	_	_	_
18-10	2149-2151	to	_	_	_	_
18-11	2152-2160	suppress	_	_	_	_
18-12	2161-2164	the	event[132]|abstract[133]	new[132]|new[133]	coref|coref	25-24[189_132]|31-13[226_133]
18-13	2165-2178	proliferation	event[132]|abstract[133]	new[132]|new[133]	_	_
18-14	2179-2182	and	abstract[133]	new[133]	_	_
18-15	2183-2193	metastatic	abstract[133]|abstract[134]	new[133]|new[134]	_	_
18-16	2194-2203	potential	abstract[133]|abstract[134]	new[133]|new[134]	_	_
18-17	2204-2206	of	abstract[133]|abstract[134]	new[133]|new[134]	_	_
18-18	2207-2213	breast	abstract[133]|abstract[134]|abstract[135]|animal[136]	new[133]|new[134]|giv[135]|giv[136]	coref|coref	19-15[146_135]|19-15[147_136]
18-19	2214-2220	cancer	abstract[133]|abstract[134]|abstract[135]|animal[136]	new[133]|new[134]|giv[135]|giv[136]	_	_
18-20	2221-2226	cells	abstract[133]|abstract[134]|animal[136]	new[133]|new[134]|giv[136]	_	_
18-21	2227-2229	by	_	_	_	_
18-22	2230-2240	inhibiting	_	_	_	_
18-23	2241-2244	Akt	abstract	new	_	_
18-24	2245-2246	,	_	_	_	_
18-25	2247-2251	AP-1	abstract	new	_	_
18-26	2252-2255	and	_	_	_	_
18-27	2256-2261	NF-κB	substance	new	_	_
18-28	2262-2263	.	_	_	_	_

#Text=Moreover , GLE modulated the estrogen receptor signaling and inhibited oxidative stress-induced invasiveness of breast cancer cells .
19-1	2264-2272	Moreover	_	_	_	_
19-2	2273-2274	,	_	_	_	_
19-3	2275-2278	GLE	abstract	giv	coref	20-16
19-4	2279-2288	modulated	_	_	_	_
19-5	2289-2292	the	abstract[143]	new[143]	_	_
19-6	2293-2301	estrogen	substance|abstract[143]	new|new[143]	_	_
19-7	2302-2310	receptor	substance|abstract[143]	new|new[143]	_	_
19-8	2311-2320	signaling	abstract[143]	new[143]	_	_
19-9	2321-2324	and	_	_	_	_
19-10	2325-2334	inhibited	_	_	_	_
19-11	2335-2344	oxidative	abstract[145]	new[145]	_	_
19-12	2345-2359	stress-induced	abstract|abstract[145]	new|new[145]	_	_
19-13	2360-2372	invasiveness	abstract[145]	new[145]	_	_
19-14	2373-2375	of	abstract[145]	new[145]	_	_
19-15	2376-2382	breast	abstract[145]|abstract[146]|animal[147]	new[145]|giv[146]|giv[147]	coref|coref	20-9[150_146]|31-18[229_147]
19-16	2383-2389	cancer	abstract[145]|abstract[146]|animal[147]	new[145]|giv[146]|giv[147]	_	_
19-17	2390-2395	cells	abstract[145]|animal[147]	new[145]|giv[147]	_	_
19-18	2396-2397	.	_	_	_	_

#Text=Consistent with the results of previous studies on breast cancer , our study showed that GLE enhanced both QCT-mediated apoptosis and EBV-lytic reactivation .
20-1	2398-2408	Consistent	_	_	_	_
20-2	2409-2413	with	_	_	_	_
20-3	2414-2417	the	abstract[148]	new[148]	coref	24-3[171_148]
20-4	2418-2425	results	abstract[148]	new[148]	_	_
20-5	2426-2428	of	abstract[148]	new[148]	_	_
20-6	2429-2437	previous	abstract[148]|abstract[149]	new[148]|new[149]	coref	38-10[273_149]
20-7	2438-2445	studies	abstract[148]|abstract[149]	new[148]|new[149]	_	_
20-8	2446-2448	on	abstract[148]|abstract[149]	new[148]|new[149]	_	_
20-9	2449-2455	breast	abstract[148]|abstract[149]|abstract[150]	new[148]|new[149]|giv[150]	coref	30-7[213_150]
20-10	2456-2462	cancer	abstract[148]|abstract[149]|abstract[150]	new[148]|new[149]|giv[150]	_	_
20-11	2463-2464	,	_	_	_	_
20-12	2465-2468	our	person|abstract[152]	acc|giv[152]	coref	34-2[240_152]
20-13	2469-2474	study	abstract[152]	giv[152]	_	_
20-14	2475-2481	showed	_	_	_	_
20-15	2482-2486	that	_	_	_	_
20-16	2487-2490	GLE	abstract	giv	coref	21-4
20-17	2491-2499	enhanced	_	_	_	_
20-18	2500-2504	both	abstract[154]|abstract[155]	giv[154]|giv[155]	coref|coref	24-9[174_154]|35-12[250_155]
20-19	2505-2517	QCT-mediated	abstract[154]|abstract[155]	giv[154]|giv[155]	_	_
20-20	2518-2527	apoptosis	abstract[154]|abstract[155]	giv[154]|giv[155]	_	_
20-21	2528-2531	and	abstract[155]	giv[155]	_	_
20-22	2532-2541	EBV-lytic	abstract[155]|abstract|event[157]	giv[155]|new|giv[157]	coref	24-15[178_157]
20-23	2542-2554	reactivation	abstract[155]|event[157]	giv[155]|giv[157]	_	_
20-24	2555-2556	.	_	_	_	_

#Text=The effects of GLE were evident at low concentrations of QCT .
21-1	2557-2560	The	abstract[158]	giv[158]	_	_
21-2	2561-2568	effects	abstract[158]	giv[158]	_	_
21-3	2569-2571	of	abstract[158]	giv[158]	_	_
21-4	2572-2575	GLE	abstract[158]|abstract	giv[158]|giv	coref	23-13
21-5	2576-2580	were	_	_	_	_
21-6	2581-2588	evident	_	_	_	_
21-7	2589-2591	at	_	_	_	_
21-8	2592-2595	low	animal[160]	new[160]	_	_
21-9	2596-2610	concentrations	animal[160]	new[160]	_	_
21-10	2611-2613	of	animal[160]	new[160]	_	_
21-11	2614-2617	QCT	animal[160]|abstract	new[160]|giv	coref	22-3
21-12	2618-2619	.	_	_	_	_

#Text=Furthermore , QCT also enhanced the GLE-mediated upregulation of the EBV gene expression .
22-1	2620-2631	Furthermore	_	_	_	_
22-2	2632-2633	,	_	_	_	_
22-3	2634-2637	QCT	abstract	giv	coref	23-6
22-4	2638-2642	also	_	_	_	_
22-5	2643-2651	enhanced	_	_	_	_
22-6	2652-2655	the	abstract[163]	new[163]	_	_
22-7	2656-2668	GLE-mediated	abstract[163]	new[163]	_	_
22-8	2669-2681	upregulation	abstract[163]	new[163]	_	_
22-9	2682-2684	of	abstract[163]	new[163]	_	_
22-10	2685-2688	the	abstract[163]|abstract[166]	new[163]|new[166]	_	_
22-11	2689-2692	EBV	abstract[163]|abstract|abstract[166]	new[163]|giv|new[166]	coref	24-16
22-12	2693-2697	gene	abstract[163]|abstract|abstract[166]	new[163]|giv|new[166]	_	_
22-13	2698-2708	expression	abstract[163]|abstract[166]	new[163]|new[166]	_	_
22-14	2709-2710	.	_	_	_	_

#Text=Similarly , the effects of QCT were evident at low concentrations of GLE .
23-1	2711-2720	Similarly	_	_	_	_
23-2	2721-2722	,	_	_	_	_
23-3	2723-2726	the	abstract[167]	new[167]	_	_
23-4	2727-2734	effects	abstract[167]	new[167]	_	_
23-5	2735-2737	of	abstract[167]	new[167]	_	_
23-6	2738-2741	QCT	abstract[167]|abstract	new[167]|giv	coref	24-13
23-7	2742-2746	were	_	_	_	_
23-8	2747-2754	evident	_	_	_	_
23-9	2755-2757	at	_	_	_	_
23-10	2758-2761	low	animal[169]	new[169]	_	_
23-11	2762-2776	concentrations	animal[169]	new[169]	_	_
23-12	2777-2779	of	animal[169]	new[169]	_	_
23-13	2780-2783	GLE	animal[169]|abstract	new[169]|giv	coref	24-7
23-14	2784-2785	.	_	_	_	_

#Text=Therefore , these results suggested that GLE enhanced QCT-mediated apoptosis , whereas QCT increased GLE-mediated EBV lytic reactivation .
24-1	2786-2795	Therefore	_	_	_	_
24-2	2796-2797	,	_	_	_	_
24-3	2798-2803	these	abstract[171]	giv[171]	_	_
24-4	2804-2811	results	abstract[171]	giv[171]	_	_
24-5	2812-2821	suggested	_	_	_	_
24-6	2822-2826	that	_	_	_	_
24-7	2827-2830	GLE	abstract	giv	coref	29-1
24-8	2831-2839	enhanced	_	_	_	_
24-9	2840-2852	QCT-mediated	abstract|abstract[174]	giv|giv[174]	coref	35-12[249_174]
24-10	2853-2862	apoptosis	abstract[174]	giv[174]	_	_
24-11	2863-2864	,	_	_	_	_
24-12	2865-2872	whereas	_	_	_	_
24-13	2873-2876	QCT	abstract	giv	coref	34-5
24-14	2877-2886	increased	_	_	_	_
24-15	2887-2899	GLE-mediated	abstract|event[178]	new|giv[178]	coref|coref	34-8[244_178]|35-15
24-16	2900-2903	EBV	abstract|event[178]	giv|giv[178]	coref	32-6
24-17	2904-2909	lytic	event[178]	giv[178]	_	_
24-18	2910-2922	reactivation	event[178]	giv[178]	_	_
24-19	2923-2924	.	_	_	_	_

#Text=Mycotherapy has several benefits , where it improves the overall response rate during cancer treatment , enhances immunity owing to the stimulation of T cell proliferation and reduces some chemotherapy-associated adverse events , such as nausea and insomnia .
25-1	2925-2936	Mycotherapy	abstract	new	ana	25-7
25-2	2937-2940	has	_	_	_	_
25-3	2941-2948	several	abstract[180]	new[180]	_	_
25-4	2949-2957	benefits	abstract[180]	new[180]	_	_
25-5	2958-2959	,	abstract[180]	new[180]	_	_
25-6	2960-2965	where	abstract[180]	new[180]	_	_
25-7	2966-2968	it	abstract[180]|abstract	new[180]|giv	coref	29-7
25-8	2969-2977	improves	abstract[180]	new[180]	_	_
25-9	2978-2981	the	abstract[180]|abstract[183]	new[180]|new[183]	_	_
25-10	2982-2989	overall	abstract[180]|abstract[183]	new[180]|new[183]	_	_
25-11	2990-2998	response	abstract[180]|event|abstract[183]	new[180]|new|new[183]	_	_
25-12	2999-3003	rate	abstract[180]|abstract[183]	new[180]|new[183]	_	_
25-13	3004-3010	during	abstract[180]	new[180]	_	_
25-14	3011-3017	cancer	abstract[180]|abstract[184]	new[180]|new[184]	coref	26-15[196_184]
25-15	3018-3027	treatment	abstract[180]|abstract[184]	new[180]|new[184]	_	_
25-16	3028-3029	,	abstract[180]	new[180]	_	_
25-17	3030-3038	enhances	abstract[180]	new[180]	_	_
25-18	3039-3047	immunity	abstract[180]|abstract	new[180]|new	_	_
25-19	3048-3053	owing	abstract[180]	new[180]	_	_
25-20	3054-3056	to	abstract[180]	new[180]	_	_
25-21	3057-3060	the	abstract[180]|event[186]	new[180]|new[186]	_	_
25-22	3061-3072	stimulation	abstract[180]|event[186]	new[180]|new[186]	_	_
25-23	3073-3075	of	abstract[180]|event[186]	new[180]|new[186]	_	_
25-24	3076-3077	T	abstract[180]|event[186]|person|place[188]|event[189]	new[180]|new[186]|new|giv[188]|giv[189]	coref	31-13[225_189]
25-25	3078-3082	cell	abstract[180]|event[186]|place[188]|event[189]	new[180]|new[186]|giv[188]|giv[189]	_	_
25-26	3083-3096	proliferation	abstract[180]|event[186]|event[189]	new[180]|new[186]|giv[189]	_	_
25-27	3097-3100	and	abstract[180]	new[180]	_	_
25-28	3101-3108	reduces	abstract[180]	new[180]	_	_
25-29	3109-3113	some	abstract[180]|event[190]	new[180]|new[190]	_	_
25-30	3114-3137	chemotherapy-associated	abstract[180]|event[190]	new[180]|new[190]	_	_
25-31	3138-3145	adverse	abstract[180]|event[190]	new[180]|new[190]	_	_
25-32	3146-3152	events	abstract[180]|event[190]	new[180]|new[190]	_	_
25-33	3153-3154	,	abstract[180]|event[190]	new[180]|new[190]	_	_
25-34	3155-3159	such	abstract[180]|event[190]	new[180]|new[190]	_	_
25-35	3160-3162	as	abstract[180]|event[190]	new[180]|new[190]	_	_
25-36	3163-3169	nausea	abstract[180]|event[190]|event	new[180]|new[190]|new	_	_
25-37	3170-3173	and	abstract[180]|event[190]	new[180]|new[190]	_	_
25-38	3174-3182	insomnia	abstract[180]|event[190]|event	new[180]|new[190]|new	_	_
25-39	3183-3184	.	_	_	_	_

#Text=Medicinal mushrooms have mainly been used in Asian countries for hundreds of years for the treatment of infectious diseases .
26-1	3185-3194	Medicinal	plant[193]	new[193]	_	_
26-2	3195-3204	mushrooms	plant[193]	new[193]	_	_
26-3	3205-3209	have	_	_	_	_
26-4	3210-3216	mainly	_	_	_	_
26-5	3217-3221	been	_	_	_	_
26-6	3222-3226	used	_	_	_	_
26-7	3227-3229	in	_	_	_	_
26-8	3230-3235	Asian	place[194]	new[194]	ana	27-4[0_194]
26-9	3236-3245	countries	place[194]	new[194]	_	_
26-10	3246-3249	for	_	_	_	_
26-11	3250-3258	hundreds	time[195]	new[195]	_	_
26-12	3259-3261	of	time[195]	new[195]	_	_
26-13	3262-3267	years	time[195]	new[195]	_	_
26-14	3268-3271	for	_	_	_	_
26-15	3272-3275	the	abstract[196]	giv[196]	coref	27-9[199_196]
26-16	3276-3285	treatment	abstract[196]	giv[196]	_	_
26-17	3286-3288	of	abstract[196]	giv[196]	_	_
26-18	3289-3299	infectious	abstract[196]|abstract[197]	giv[196]|new[197]	_	_
26-19	3300-3308	diseases	abstract[196]|abstract[197]	giv[196]|new[197]	_	_
26-20	3309-3310	.	_	_	_	_

#Text=More recently , they have been used for cancer treatment as adjuncts .
27-1	3311-3315	More	_	_	_	_
27-2	3316-3324	recently	_	_	_	_
27-3	3325-3326	,	_	_	_	_
27-4	3327-3331	they	place	giv	ana	28-3
27-5	3332-3336	have	_	_	_	_
27-6	3337-3341	been	_	_	_	_
27-7	3342-3346	used	_	_	_	_
27-8	3347-3350	for	_	_	_	_
27-9	3351-3357	cancer	abstract[199]	giv[199]	_	_
27-10	3358-3367	treatment	abstract[199]	giv[199]	_	_
27-11	3368-3370	as	_	_	_	_
27-12	3371-3379	adjuncts	abstract	new	_	_
27-13	3380-3381	.	_	_	_	_

#Text=Importantly , they have an extensive clinical history of safe use as single agents or in combination with chemotherapy .
28-1	3382-3393	Importantly	_	_	_	_
28-2	3394-3395	,	_	_	_	_
28-3	3396-3400	they	place	giv	_	_
28-4	3401-3405	have	_	_	_	_
28-5	3406-3408	an	abstract[202]	new[202]	_	_
28-6	3409-3418	extensive	abstract[202]	new[202]	_	_
28-7	3419-3427	clinical	abstract[202]	new[202]	_	_
28-8	3428-3435	history	abstract[202]	new[202]	_	_
28-9	3436-3438	of	abstract[202]	new[202]	_	_
28-10	3439-3443	safe	abstract[202]|event[203]	new[202]|new[203]	coref	39-3[274_203]
28-11	3444-3447	use	abstract[202]|event[203]	new[202]|new[203]	_	_
28-12	3448-3450	as	abstract[202]|event[203]	new[202]|new[203]	_	_
28-13	3451-3457	single	abstract[202]|event[203]|person[204]	new[202]|new[203]|giv[204]	_	_
28-14	3458-3464	agents	abstract[202]|event[203]|person[204]	new[202]|new[203]|giv[204]	_	_
28-15	3465-3467	or	_	_	_	_
28-16	3468-3470	in	_	_	_	_
28-17	3471-3482	combination	_	_	_	_
28-18	3483-3487	with	_	_	_	_
28-19	3488-3500	chemotherapy	substance	new	coref	39-21[279_0]
28-20	3501-3502	.	_	_	_	_

#Text=GLE has been intensively combined with mycotherapy for the treatment of broad-spectrum cancers .
29-1	3503-3506	GLE	abstract	giv	coref	30-1
29-2	3507-3510	has	_	_	_	_
29-3	3511-3515	been	_	_	_	_
29-4	3516-3527	intensively	_	_	_	_
29-5	3528-3536	combined	_	_	_	_
29-6	3537-3541	with	_	_	_	_
29-7	3542-3553	mycotherapy	abstract	giv	_	_
29-8	3554-3557	for	_	_	_	_
29-9	3558-3561	the	abstract[208]	new[208]	_	_
29-10	3562-3571	treatment	abstract[208]	new[208]	_	_
29-11	3572-3574	of	abstract[208]	new[208]	_	_
29-12	3575-3589	broad-spectrum	abstract[208]|abstract[209]	new[208]|new[209]	_	_
29-13	3590-3597	cancers	abstract[208]|abstract[209]	new[208]|new[209]	_	_
29-14	3598-3599	.	_	_	_	_

#Text=GLE has shown antitumor activities against breast cancer , bladder cancer , prostate cancer , colorectal cancer and others .
30-1	3600-3603	GLE	abstract	giv	coref	31-6
30-2	3604-3607	has	_	_	_	_
30-3	3608-3613	shown	_	_	_	_
30-4	3614-3623	antitumor	abstract|abstract[212]	giv|giv[212]	coref	36-18
30-5	3624-3634	activities	abstract[212]	giv[212]	_	_
30-6	3635-3642	against	abstract[212]	giv[212]	_	_
30-7	3643-3649	breast	abstract[212]|abstract[213]	giv[212]|giv[213]	coref	30-10[215_213]
30-8	3650-3656	cancer	abstract[212]|abstract[213]	giv[212]|giv[213]	_	_
30-9	3657-3658	,	abstract[212]	giv[212]	_	_
30-10	3659-3666	bladder	abstract[212]|object|abstract[215]	giv[212]|new|giv[215]	coref	30-13[217_215]
30-11	3667-3673	cancer	abstract[212]|abstract[215]	giv[212]|giv[215]	_	_
30-12	3674-3675	,	abstract[212]	giv[212]	_	_
30-13	3676-3684	prostate	abstract[212]|place|abstract[217]	giv[212]|new|giv[217]	coref	30-16[218_217]
30-14	3685-3691	cancer	abstract[212]|abstract[217]	giv[212]|giv[217]	_	_
30-15	3692-3693	,	abstract[212]	giv[212]	_	_
30-16	3694-3704	colorectal	abstract[212]|abstract[218]	giv[212]|giv[218]	coref	31-18[0_218]
30-17	3705-3711	cancer	abstract[212]|abstract[218]	giv[212]|giv[218]	_	_
30-18	3712-3715	and	abstract[212]	giv[212]	_	_
30-19	3716-3722	others	abstract[212]|person	giv[212]|new	_	_
30-20	3723-3724	.	_	_	_	_

#Text=These tumor inhibitory effects of GLE were attributed to the disruption of the proliferation and metastasis of cancer cells .
31-1	3725-3730	These	abstract[222]	new[222]	_	_
31-2	3731-3736	tumor	abstract|abstract[222]	new|new[222]	_	_
31-3	3737-3747	inhibitory	abstract|abstract[222]	new|new[222]	_	_
31-4	3748-3755	effects	abstract[222]	new[222]	_	_
31-5	3756-3758	of	abstract[222]	new[222]	_	_
31-6	3759-3762	GLE	abstract[222]|abstract	new[222]|giv	coref	35-6
31-7	3763-3767	were	_	_	_	_
31-8	3768-3778	attributed	_	_	_	_
31-9	3779-3781	to	_	_	_	_
31-10	3782-3785	the	event[224]	new[224]	_	_
31-11	3786-3796	disruption	event[224]	new[224]	_	_
31-12	3797-3799	of	event[224]	new[224]	_	_
31-13	3800-3803	the	event[224]|event[225]|abstract[226]	new[224]|giv[225]|giv[226]	_	_
31-14	3804-3817	proliferation	event[224]|event[225]|abstract[226]	new[224]|giv[225]|giv[226]	_	_
31-15	3818-3821	and	event[224]|abstract[226]	new[224]|giv[226]	_	_
31-16	3822-3832	metastasis	event[224]|abstract[226]|abstract[227]	new[224]|giv[226]|new[227]	_	_
31-17	3833-3835	of	event[224]|abstract[226]|abstract[227]	new[224]|giv[226]|new[227]	_	_
31-18	3836-3842	cancer	event[224]|abstract[226]|abstract[227]|abstract|animal[229]	new[224]|giv[226]|new[227]|giv|giv[229]	_	_
31-19	3843-3848	cells	event[224]|abstract[226]|abstract[227]|animal[229]	new[224]|giv[226]|new[227]|giv[229]	_	_
31-20	3849-3850	.	_	_	_	_

#Text=However , the fact that EBV is the initiator of gastric carcinoma should be considered in the treatment of EBVaGC .
32-1	3851-3858	However	_	_	_	_
32-2	3859-3860	,	_	_	_	_
32-3	3861-3864	the	abstract[230]	new[230]	_	_
32-4	3865-3869	fact	abstract[230]	new[230]	_	_
32-5	3870-3874	that	abstract[230]	new[230]	_	_
32-6	3875-3878	EBV	abstract[230]|abstract|abstract[232]	new[230]|giv|new[232]	coref	33-1
32-7	3879-3881	is	abstract[230]|abstract[232]	new[230]|new[232]	_	_
32-8	3882-3885	the	abstract[230]|abstract[232]	new[230]|new[232]	_	_
32-9	3886-3895	initiator	abstract[230]|abstract[232]	new[230]|new[232]	_	_
32-10	3896-3898	of	abstract[230]|abstract[232]	new[230]|new[232]	_	_
32-11	3899-3906	gastric	abstract[230]|abstract[232]|object[233]	new[230]|new[232]|giv[233]	_	_
32-12	3907-3916	carcinoma	abstract[230]|abstract[232]|object[233]	new[230]|new[232]|giv[233]	_	_
32-13	3917-3923	should	_	_	_	_
32-14	3924-3926	be	_	_	_	_
32-15	3927-3937	considered	_	_	_	_
32-16	3938-3940	in	_	_	_	_
32-17	3941-3944	the	abstract[234]	new[234]	coref	36-23[261_234]
32-18	3945-3954	treatment	abstract[234]	new[234]	_	_
32-19	3955-3957	of	abstract[234]	new[234]	_	_
32-20	3958-3964	EBVaGC	abstract[234]|abstract	new[234]|giv	coref	33-10
32-21	3965-3966	.	_	_	_	_

#Text=EBV should be eliminated to reduce the risk of EBVaGC relapse .
33-1	3967-3970	EBV	abstract	giv	coref	34-8
33-2	3971-3977	should	_	_	_	_
33-3	3978-3980	be	_	_	_	_
33-4	3981-3991	eliminated	_	_	_	_
33-5	3992-3994	to	_	_	_	_
33-6	3995-4001	reduce	_	_	_	_
33-7	4002-4005	the	abstract[237]	new[237]	_	_
33-8	4006-4010	risk	abstract[237]	new[237]	_	_
33-9	4011-4013	of	abstract[237]	new[237]	_	_
33-10	4014-4020	EBVaGC	abstract[237]|abstract|event[239]	new[237]|giv|new[239]	coref	36-23
33-11	4021-4028	relapse	abstract[237]|event[239]	new[237]|new[239]	_	_
33-12	4029-4030	.	_	_	_	_

#Text=In this study , QCT strongly induced EBV lytic reactivation .
34-1	4031-4033	In	_	_	_	_
34-2	4034-4038	this	abstract[240]	giv[240]	_	_
34-3	4039-4044	study	abstract[240]	giv[240]	_	_
34-4	4045-4046	,	_	_	_	_
34-5	4047-4050	QCT	abstract	giv	coref	35-8
34-6	4051-4059	strongly	_	_	_	_
34-7	4060-4067	induced	_	_	_	_
34-8	4068-4071	EBV	abstract|event[244]	giv|giv[244]	coref|coref	35-16|35-15[253_244]
34-9	4072-4077	lytic	abstract|event[244]	new|giv[244]	_	_
34-10	4078-4090	reactivation	event[244]	giv[244]	_	_
34-11	4091-4092	.	_	_	_	_

#Text=The synergistic effects of the GLE and QCT cotreatment might enhance QCT-mediated apoptosis and GLE-mediated EBV lytic reactivation .
35-1	4093-4096	The	abstract[245]	new[245]	coref	38-1[270_245]
35-2	4097-4108	synergistic	abstract[245]	new[245]	_	_
35-3	4109-4116	effects	abstract[245]	new[245]	_	_
35-4	4117-4119	of	abstract[245]	new[245]	_	_
35-5	4120-4123	the	abstract[245]|abstract[248]	new[245]|new[248]	_	_
35-6	4124-4127	GLE	abstract[245]|abstract|abstract[248]	new[245]|giv|new[248]	coref	36-3[255_0]
35-7	4128-4131	and	abstract[245]|abstract[248]	new[245]|new[248]	_	_
35-8	4132-4135	QCT	abstract[245]|abstract|abstract[248]	new[245]|giv|new[248]	coref	39-9
35-9	4136-4147	cotreatment	abstract[245]|abstract[248]	new[245]|new[248]	_	_
35-10	4148-4153	might	_	_	_	_
35-11	4154-4161	enhance	_	_	_	_
35-12	4162-4174	QCT-mediated	abstract[249]|abstract[250]	giv[249]|giv[250]	_	_
35-13	4175-4184	apoptosis	abstract[249]|abstract[250]	giv[249]|giv[250]	_	_
35-14	4185-4188	and	abstract[250]	giv[250]	_	_
35-15	4189-4201	GLE-mediated	abstract[250]|abstract|event[253]	giv[250]|giv|giv[253]	_	_
35-16	4202-4205	EBV	abstract[250]|abstract|event[253]	giv[250]|giv|giv[253]	_	_
35-17	4206-4211	lytic	abstract[250]|event[253]	giv[250]|giv[253]	_	_
35-18	4212-4224	reactivation	abstract[250]|event[253]	giv[250]|giv[253]	_	_
35-19	4225-4226	.	_	_	_	_

#Text=Therefore , QCT-supplemented GLE might be used as a medicinal food with a dual function as an antitumor and antiviral agent for EBVaGC treatment .
36-1	4227-4236	Therefore	_	_	_	_
36-2	4237-4238	,	_	_	_	_
36-3	4239-4255	QCT-supplemented	abstract|abstract[255]	new|giv[255]	coref|coref	37-15|37-15[267_255]
36-4	4256-4259	GLE	abstract[255]	giv[255]	_	_
36-5	4260-4265	might	_	_	_	_
36-6	4266-4268	be	_	_	_	_
36-7	4269-4273	used	_	_	_	_
36-8	4274-4276	as	_	_	_	_
36-9	4277-4278	a	substance[256]	new[256]	_	_
36-10	4279-4288	medicinal	substance[256]	new[256]	_	_
36-11	4289-4293	food	substance[256]	new[256]	_	_
36-12	4294-4298	with	substance[256]	new[256]	_	_
36-13	4299-4300	a	substance[256]|abstract[257]	new[256]|giv[257]	ana	37-7[0_257]
36-14	4301-4305	dual	substance[256]|abstract[257]	new[256]|giv[257]	_	_
36-15	4306-4314	function	substance[256]|abstract[257]	new[256]|giv[257]	_	_
36-16	4315-4317	as	substance[256]|abstract[257]	new[256]|giv[257]	_	_
36-17	4318-4320	an	substance[256]|abstract[257]|substance[259]	new[256]|giv[257]|new[259]	_	_
36-18	4321-4330	antitumor	substance[256]|abstract[257]|abstract|substance[259]	new[256]|giv[257]|giv|new[259]	coref	38-3
36-19	4331-4334	and	substance[256]|abstract[257]|substance[259]	new[256]|giv[257]|new[259]	_	_
36-20	4335-4344	antiviral	substance[256]|abstract[257]|substance[259]	new[256]|giv[257]|new[259]	_	_
36-21	4345-4350	agent	substance[256]|abstract[257]|substance[259]	new[256]|giv[257]|new[259]	_	_
36-22	4351-4354	for	substance[256]|abstract[257]	new[256]|giv[257]	_	_
36-23	4355-4361	EBVaGC	substance[256]|abstract[257]|abstract|abstract[261]	new[256]|giv[257]|giv|giv[261]	coref|coref	37-22|39-14[277_261]
36-24	4362-4371	treatment	substance[256]|abstract[257]|abstract[261]	new[256]|giv[257]|giv[261]	_	_
36-25	4372-4373	.	_	_	_	_

#Text=To the author ’s knowledge , this is the first study to report that QCT-supplemented GLE might be effective in treating EBVaGC .
37-1	4374-4376	To	_	_	_	_
37-2	4377-4380	the	abstract[263]	new[263]	_	_
37-3	4381-4387	author	person[262]|abstract[263]	new[262]|new[263]	_	_
37-4	4388-4390	’s	person[262]|abstract[263]	new[262]|new[263]	_	_
37-5	4391-4400	knowledge	abstract[263]	new[263]	_	_
37-6	4401-4402	,	_	_	_	_
37-7	4403-4407	this	abstract	giv	coref	37-9[265_0]
37-8	4408-4410	is	_	_	_	_
37-9	4411-4414	the	abstract[265]	giv[265]	coref	39-25[280_265]
37-10	4415-4420	first	abstract[265]	giv[265]	_	_
37-11	4421-4426	study	abstract[265]	giv[265]	_	_
37-12	4427-4429	to	abstract[265]	giv[265]	_	_
37-13	4430-4436	report	abstract[265]	giv[265]	_	_
37-14	4437-4441	that	abstract[265]	giv[265]	_	_
37-15	4442-4458	QCT-supplemented	abstract[265]|abstract|abstract[267]	giv[265]|giv|giv[267]	coref|coref	39-7[0_267]|40-22
37-16	4459-4462	GLE	abstract[265]|abstract[267]	giv[265]|giv[267]	_	_
37-17	4463-4468	might	abstract[265]	giv[265]	_	_
37-18	4469-4471	be	abstract[265]	giv[265]	_	_
37-19	4472-4481	effective	abstract[265]	giv[265]	_	_
37-20	4482-4484	in	_	_	_	_
37-21	4485-4493	treating	_	_	_	_
37-22	4494-4500	EBVaGC	abstract	giv	_	_
37-23	4501-4502	.	_	_	_	_

#Text=The synergistic antitumor and antiviral effects were supported by both in vivo and in vitro studies .
38-1	4503-4506	The	abstract[270]	giv[270]	_	_
38-2	4507-4518	synergistic	abstract[270]	giv[270]	_	_
38-3	4519-4528	antitumor	abstract|abstract[270]	giv|giv[270]	coref	40-17
38-4	4529-4532	and	abstract[270]	giv[270]	_	_
38-5	4533-4542	antiviral	abstract[270]	giv[270]	_	_
38-6	4543-4550	effects	abstract[270]	giv[270]	_	_
38-7	4551-4555	were	_	_	_	_
38-8	4556-4565	supported	_	_	_	_
38-9	4566-4568	by	_	_	_	_
38-10	4569-4573	both	abstract[271]|abstract[273]	new[271]|giv[273]	coref	40-3[281_273]
38-11	4574-4576	in	abstract[271]|abstract[273]	new[271]|giv[273]	_	_
38-12	4577-4581	vivo	abstract[271]|abstract[273]	new[271]|giv[273]	_	_
38-13	4582-4585	and	abstract[273]	giv[273]	_	_
38-14	4586-4588	in	abstract[273]	giv[273]	_	_
38-15	4589-4594	vitro	organization|abstract[273]	new|giv[273]	_	_
38-16	4595-4602	studies	abstract[273]	giv[273]	_	_
38-17	4603-4604	.	_	_	_	_

#Text=Hence , the combined use of GLE and QCT could be beneficial in cancer treatment by alleviating the toxicity of conventional chemotherapy and improving the immune function .
39-1	4605-4610	Hence	_	_	_	_
39-2	4611-4612	,	_	_	_	_
39-3	4613-4616	the	event[274]	giv[274]	_	_
39-4	4617-4625	combined	event[274]	giv[274]	_	_
39-5	4626-4629	use	event[274]	giv[274]	_	_
39-6	4630-4632	of	event[274]	giv[274]	_	_
39-7	4633-4636	GLE	event[274]|abstract	giv[274]|giv	coref	40-22[286_0]
39-8	4637-4640	and	event[274]	giv[274]	_	_
39-9	4641-4644	QCT	event[274]|abstract	giv[274]|giv	_	_
39-10	4645-4650	could	_	_	_	_
39-11	4651-4653	be	_	_	_	_
39-12	4654-4664	beneficial	_	_	_	_
39-13	4665-4667	in	_	_	_	_
39-14	4668-4674	cancer	abstract[277]	giv[277]	_	_
39-15	4675-4684	treatment	abstract[277]	giv[277]	_	_
39-16	4685-4687	by	_	_	_	_
39-17	4688-4699	alleviating	_	_	_	_
39-18	4700-4703	the	abstract[278]	new[278]	_	_
39-19	4704-4712	toxicity	abstract[278]	new[278]	_	_
39-20	4713-4715	of	abstract[278]	new[278]	_	_
39-21	4716-4728	conventional	abstract[278]|substance[279]	new[278]|giv[279]	_	_
39-22	4729-4741	chemotherapy	abstract[278]|substance[279]	new[278]|giv[279]	_	_
39-23	4742-4745	and	_	_	_	_
39-24	4746-4755	improving	_	_	_	_
39-25	4756-4759	the	abstract[280]	giv[280]	_	_
39-26	4760-4766	immune	abstract[280]	giv[280]	_	_
39-27	4767-4775	function	abstract[280]	giv[280]	_	_
39-28	4776-4777	.	_	_	_	_

#Text=However , more studies are still needed to further elucidate the molecular mechanisms of the direct antitumor and antiviral effects of QCT-supplemented GLE .
40-1	4778-4785	However	_	_	_	_
40-2	4786-4787	,	_	_	_	_
40-3	4788-4792	more	abstract[281]	giv[281]	_	_
40-4	4793-4800	studies	abstract[281]	giv[281]	_	_
40-5	4801-4804	are	_	_	_	_
40-6	4805-4810	still	_	_	_	_
40-7	4811-4817	needed	_	_	_	_
40-8	4818-4820	to	_	_	_	_
40-9	4821-4828	further	_	_	_	_
40-10	4829-4838	elucidate	_	_	_	_
40-11	4839-4842	the	abstract[282]	new[282]	_	_
40-12	4843-4852	molecular	abstract[282]	new[282]	_	_
40-13	4853-4863	mechanisms	abstract[282]	new[282]	_	_
40-14	4864-4866	of	abstract[282]	new[282]	_	_
40-15	4867-4870	the	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-16	4871-4877	direct	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-17	4878-4887	antitumor	abstract[282]|abstract|abstract[284]	new[282]|giv|new[284]	_	_
40-18	4888-4891	and	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-19	4892-4901	antiviral	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-20	4902-4909	effects	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-21	4910-4912	of	abstract[282]|abstract[284]	new[282]|new[284]	_	_
40-22	4913-4929	QCT-supplemented	abstract[282]|abstract[284]|abstract|abstract[286]	new[282]|new[284]|giv|giv[286]	_	_
40-23	4930-4933	GLE	abstract[282]|abstract[284]|abstract[286]	new[282]|new[284]|giv[286]	_	_
40-24	4934-4935	.	_	_	_	_
